eli lilly glp-1 pill data stock soars on encouraging results for daily weight-loss Eli Lilly to seek approval

After a two-year-long shortage, the FDA announced that Eli Lillys GLP-1 drug Mounjaro, and obesity version Zepbound, are back in stock.

Learn when and how to introduce GLP-1 during weight management consultations using evidence-based approach for sustainable results.

Employers can't shirk responsibility for novel weight loss drugs forever, executives argued at a recent Newsweek event.

Now Pfizers public declaration that its at the end of the beginning in entering the GLP1 market marks a pivotal

Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity

GLP-1 drugs show modest weight loss (~5%) in breast cancer patients, highlighting potential as supportive therapy.